1. Home
  2. CTLP vs GERN Comparison

CTLP vs GERN Comparison

Compare CTLP & GERN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CTLP
  • GERN
  • Stock Information
  • Founded
  • CTLP 1992
  • GERN 1990
  • Country
  • CTLP United States
  • GERN United States
  • Employees
  • CTLP N/A
  • GERN N/A
  • Industry
  • CTLP EDP Services
  • GERN Biotechnology: Pharmaceutical Preparations
  • Sector
  • CTLP Technology
  • GERN Health Care
  • Exchange
  • CTLP Nasdaq
  • GERN Nasdaq
  • Market Cap
  • CTLP 776.5M
  • GERN 740.5M
  • IPO Year
  • CTLP N/A
  • GERN 1996
  • Fundamental
  • Price
  • CTLP $10.70
  • GERN $1.10
  • Analyst Decision
  • CTLP Hold
  • GERN Buy
  • Analyst Count
  • CTLP 3
  • GERN 7
  • Target Price
  • CTLP N/A
  • GERN $3.00
  • AVG Volume (30 Days)
  • CTLP 729.3K
  • GERN 8.2M
  • Earning Date
  • CTLP 11-06-2025
  • GERN 11-05-2025
  • Dividend Yield
  • CTLP N/A
  • GERN N/A
  • EPS Growth
  • CTLP 371.48
  • GERN N/A
  • EPS
  • CTLP 0.80
  • GERN N/A
  • Revenue
  • CTLP $312,565,000.00
  • GERN $183,403,000.00
  • Revenue This Year
  • CTLP $18.25
  • GERN $166.20
  • Revenue Next Year
  • CTLP $12.30
  • GERN $55.83
  • P/E Ratio
  • CTLP $13.35
  • GERN N/A
  • Revenue Growth
  • CTLP 12.94
  • GERN 522.13
  • 52 Week Low
  • CTLP $7.01
  • GERN $1.04
  • 52 Week High
  • CTLP $11.36
  • GERN $4.21
  • Technical
  • Relative Strength Index (RSI)
  • CTLP 65.36
  • GERN 39.95
  • Support Level
  • CTLP $10.50
  • GERN $1.04
  • Resistance Level
  • CTLP $10.60
  • GERN $1.28
  • Average True Range (ATR)
  • CTLP 0.05
  • GERN 0.07
  • MACD
  • CTLP 0.02
  • GERN -0.00
  • Stochastic Oscillator
  • CTLP 93.18
  • GERN 22.00

About CTLP Cantaloupe Inc.

Cantaloupe Inc is a technology leader powering self-service commerce by offering one integrated solution for payments processing, logistics, and back-office management. The group offers a comprehensive suite of solutions, including micro-payment processing, self-checkout kiosks, mobile ordering, connected point-of-sale (POS) systems, and enterprise cloud software. Its product and services portfolio consists of Card Readers, Self-Service Kiosks, Smart Coolers, Seed Pick Easy, Cantaloupe Go, Cheq, Smart Lock Connect, and Vine Digital Studio. The company derives revenue streams from subscriptions, transaction processing, and equipment sales.

About GERN Geron Corporation

Geron Corp is a clinical-stage biopharmaceutical company focused on the research and development of cancer treatments. The company's drug in development, Imelstat, is being tested for the treatment of myelodysplastic syndromes, which are disorders of the blood, and myelofibrosis, which is a rare blood cancer affecting bone marrow. The company earns revenue through collaboration agreements, milestones, royalties, and licensing arrangements. Geron possesses various rights to this drug. The company operates as a single segment being, the development of therapeutic products for oncology.

Share on Social Networks: